Toxicological Research

  • 제14권3호
  • /
  • Pages.307-313
  • /
  • 1998
  • /
  • 1976-8257(pISSN)
  • /
  • 2234-2753(eISSN)
한국독성학회 (Korean Society of Toxicology & Korea Environmental Mutagen Society)
권호 표지

새로운 간염치료제인 수용성 DDB 유도체 (DDB-S)의 항원성 평가

Antigenicity of a Water Soluble Dimethyl Dimethoxy Biphenylate Derivative(DDB-S), a New Antihepatitis Agent

  • 한형미 (독성부 면역독성과, 국립독성연구소, 식품의약품안전청) ;
  • 김진호 (독성부 면역독성과, 국립독성연구소, 식품의약품안전청) ;
  • 최경백 (독성부 면역독성과, 국립독성연구소, 식품의약품안전청) ;
  • 김형수 (독성부 면역독성과, 국립독성연구소, 식품의약품안전청) ;
  • 정승태 (독성부 면역독성과, 국립독성연구소, 식품의약품안전청) ;
  • 문전옥 (부산대학교 약학대학) ;
  • 이치호 (부산대학교 약학대학) ;
  • 김주일 (독성부 면역독성과, 국립독성연구소, 식품의약품안전청)
  • Han, Hyung-Mee (Immutoxicology Division, Department of Toxicology, National Institute of Toxicological Resarch, Korea Food and Administration) ;
  • Kim, Jin-Ho (Immutoxicology Division, Department of Toxicology, National Institute of Toxicological Resarch, Korea Food and Administration) ;
  • Choi, Kyoung-Baek (Immutoxicology Division, Department of Toxicology, National Institute of Toxicological Resarch, Korea Food and Administration) ;
  • Kim, Hyung-Soo (Immutoxicology Division, Department of Toxicology, National Institute of Toxicological Resarch, Korea Food and Administration) ;
  • Chung, Seung-Tae (Immutoxicology Division, Department of Toxicology, National Institute of Toxicological Resarch, Korea Food and Administration) ;
  • Moon, Jeon-Ok (College of Pharmacy, Pusan National University) ;
  • Lee, Chi-Ho (College of Pharmacy, Pusan National University) ;
  • Kim, Joo-Il (Immutoxicology Division, Department of Toxicology, National Institute of Toxicological Resarch, Korea Food and Administration)
  • 발행 : 1998.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Dimethyl dimethoxy biphenylate (DDB) is an agent used to treat hepatits. DDB-S (DDB-soluble), a new DDB derivative, was synthsized to increase water solubility of the original DDB. In the present study, the antigenic potential of DDB-S was examined by active systemic anaphylaxis (ASA), passive cutaneous anaphylaxis (PCA) and passive hemagglutination (PHA) tests. The experimental groups consist of a low dosage group, a high dosage group, he group emulsified with Freund's complete adjuvant (FCA, ASA test) or an alum (PCA and PHA tests) and the macromolecule conjugate group emulsified with FCA or an alum. In the ASA test, all experimental groups showed negative responses whereas the positive control group given ovalbumin plus FCA showed severe anaphylactic responses. In the heterologous PCA test using mice and rats, positive responses were not detected in any of the experimental groups. In the PHA test, all experimental groups showed negative responses whereas the positive control group given ovalbumin plus an alum showed 512~2048 PHA titers. These results demonstrated that DDB-S does not have any antigenic potential. These can be utilized as a part of preclinical data for the development of DDB-S as an intravenous injection.

키워드